The ENZA-p trial analyzed the activity and safety of enzalutamide with [177Lu]Lu-PSMA-617 (a radiopharmaceutical containing prostate-specific membrane antigen) versus enzalutamide alone as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC). New data have elaborated on the study’s findings along with additional follow-up information. ...
RLT
![ENZA-p Trial: Enzalutamide With [177Lu]Lu-PSMA-617 Improves OS in mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2022/12/Prostate-3.0.png)
Advertisement
Latest News
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Advertisement
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Section Editor
Oliver Sartor, MDDepartment of Oncology | Mayo Clinic
Advertisement
Roundtables
The panel discusses lutetium-177-PSMA for the treatment of advanced prostate cancer and reviews the VISION trial.
Panel experts discuss PSMA-targeting agents currently being assessed, including PSMA-I&T-Lutetium-177.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.